Kisqali (ribociclib) - Novartis
Kisqali: Regulatory submission for HR+, HER2(-) breast cancer (adjuvant) in 2023 or later (Novartis) - Oct 22, 2019 - Q3 2019 Results 
Regulatory
https://www.novartis.com/sites/www.novartis.com/files/q3-2019-ir-presentation.pdf
 
Oct 22, 2019
 
 
d6c5718c-6789-4b2c-8959-51842d1e1052.jpg